OncClubAll Oncology NewsPipeline Report
InsightsMedical World NewsOncChatsOncLive News Network®OncLive TVPeer ExchangePodcastsRapid ReadoutsThe Talk
Conference CoverageConference Listing
Giants of Cancer CarePER EventsScientific InterchangesState of the Science Summit / IPCWebinars
Partners
Oncology Live®Oncology FellowsSupplements And Featured PublicationsAll Publications
CME/CE
Biomarker ConsortiumInteractive ToolsLearning ModulesPresentationsSponsored
Print SubscriptioneNewsletter
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
Business Management
CAR T-cell Therapy
COVID-19
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Immuno-OncologyImmuno-OncologyImmuno-OncologyImmuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Nursing News
Pediatric Oncology
Precision Medicine in Oncology®Precision Medicine in Oncology®
Sarcomas/TGCT
Supportive Care
Spotlight -
  • REGISTER TODAY to explore data on a novel second-generation BTK inhibitor for adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
  • Share your views with OncChats
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
Business Management
CAR T-cell Therapy
COVID-19
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Immuno-OncologyImmuno-OncologyImmuno-OncologyImmuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Nursing News
Pediatric Oncology
Precision Medicine in Oncology®Precision Medicine in Oncology®
Sarcomas/TGCT
Supportive Care
    • Partners
    • CME/CE
Advertisement

Updates in the Management of Neuroendocrine Tumors

home / news-network / management-of-neuroendocrine-tumors
Advertisement

EP. 1: NETs Treatment Landscape and Selection Factors

By Pamela L. Kunz, MD, Yale School of Medicine
June 19th 2020
Optimal Sequencing Strategy for NETs

EP. 2: Optimal Sequencing Strategy for NETs

By Pamela L. Kunz, MD, Yale School of Medicine
June 19th 2020
New Biomarkers for Diagnosis and Prognosis

EP. 3: New Biomarkers for Diagnosis and Prognosis

By Pamela L. Kunz, MD, Yale School of Medicine
June 19th 2020
Inoperable NETs: The Role of Systemic Therapy

EP. 4: Inoperable NETs: The Role of Systemic Therapy

By Pamela L. Kunz, MD, Yale School of Medicine
June 19th 2020
Subcutaneous Pen Formulation FDA Approval

EP. 5: Subcutaneous Pen Formulation FDA Approval

By Pamela L. Kunz, MD, Yale School of Medicine
June 19th 2020
NETTER-1 Clinical Trial Overview

EP. 6: NETTER-1 Clinical Trial Overview

By Pamela L. Kunz, MD, Yale School of Medicine
June 19th 2020
Advertisement
NETs Data Updates at ASCO 2020

EP. 7: NETs Data Updates at ASCO 2020

By Pamela L. Kunz, MD, Yale School of Medicine
June 19th 2020
NETs Management: Unmet Needs and Future Direction

EP. 8: NETs Management: Unmet Needs and Future Direction

By Pamela L. Kunz, MD, Yale School of Medicine
June 19th 2020

Latest Conference Coverage

Lung Responses to Atezolizumab/Bevacizumab Linked With OS in HCC and Pulmonary Metastasis

Second-Line Regorafenib Demonstrates Safety in Advanced HCC, Irrespective of Prior Treatment

First-line Toripalimab Plus Sorafenib Elicits Responses in Unresectable Hepatocellular Carcinoma

Data for Luspatercept Highlight Evolving Treatment Landscape in Lower-Risk MDS

View More Latest Conference Coverage
Advertise
About OncLive
Editorial Board
CancerNetwork.com
CGTlive.com
CureToday.com
OncNursingNews.com
TargetedOnc.com
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.
Home
About Us
News
Contact